Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer

OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m(2) every 3 weeks with daily prednisone 10 mg) was combined...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BJU Int
Main Authors: Madan, Ravi A., Karzai, Fatima H., Harthy, Munjid Al, Petrylak, Daniel P., Kim, Joseph W., Arlen, Philip M., Rosner, Inger, Theoret, Marc R., Cordes, Lisa, Bilusic, Marijo, Peer, Cody J., Dawson, Nancy A., Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Chun, Guin, Owens, Helen, Marte, Jennifer L., Lee, Min-Jung, Tomita, Yusuke, Yuno, Akira, Trepel, Jane B., Lee, Sunmin, Steinberg, Seth M., Gulley, James L., Figg, William D., Dahut, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265825/
https://ncbi.nlm.nih.gov/pubmed/32969563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.15227
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados